Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

✍ Scribed by Gabriele Buda; Deborah Ricci; C. Chris Huang; Reyna Favis; Nadine Cohen; Sen H. Zhuang; Jean-Luc Harousseau; Pieter Sonneveld; Joan Bladé; Robert Z. Orlowski

• Publisher: Springer
• Year: 2010
• Tongue: English
• Weight: 264 KB
• Volume: 89
• Category: Article
• ISSN: 0939-5555
• DOI: 10.1007/s00277-010-0992-3